Please login to the form below

Not currently logged in
Email:
Password:

Isentress

This page shows the latest Isentress news and features for those working in and with pharma, biotech and healthcare.

A new option for people with HIV

A new option for people with HIV

Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... tenofovir disoproxil fumarate (Atripla) and raltegravir (Isentress).

Latest news

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    FDA clears Isentress formulation for infants with HIV. Merck's integrase inhibitor available for children as young as four weeks. ... By expanding the potential audience of Isentress, Merck will hope it can keep up in an increasingly competitive market

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year ... As the first entrant, Isentress is enjoying

  • ViiV gets US nod for HIV drug dolutegravir ViiV gets US nod for HIV drug dolutegravir

    a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients. ... The SAILING study found that Tivicay was more effective than Isentress in suppressing

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)

  • GSK boost vaccines capabilities with €250m Okairos purchase GSK boost vaccines capabilities with €250m Okairos purchase

    It was founded by the same team who founded Istituto di Ricerche di Biologia Molecolare (IRBM) – the company that discovered HIV treatment Isentress (raltegravir) before becoming a subsidiary of Merck.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics